Skip to main
  1. Stocks
  2. Attovia Therapeutics Inc
  3. Forecast
ATTO

ATTO Stock Forecast & Price Target

ATTO Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 20%
Buy 80%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Attovia Therapeutics is viewed favorably because its ATTOBODY platform can generate differentiated mono-, bi-, and trispecific biologics against validated immune targets, potentially creating a durable pipeline in large, underserved I&I markets. ATTO-1310 already showed promising 4-week itch reduction signals and is modeled to reach 49,469 treated patients with $1.875 billion in U.S. sales across CPUO, high-itch AD, cholestatic pruritus, and CKD-aP, while YTE half-life extension could support quarterly maintenance dosing and better convenience. ATTO-2306 and ATTO-1091 add further upside through rational multi-target designs in AD and IBD, with early preclinical data and upcoming 2027 clinical starts supporting a long runway for value creation.

Bears say

Attovia Therapeutics is viewed skeptically because its lead programs face a crowded competitive landscape in AD and IBD, where IL-13, IL-31, and bispecific/trispecific approaches have already raised the efficacy bar and may limit differentiation. The company also carries meaningful clinical risk: the IL-31 ligand strategy may not outperform receptor antagonists, ATTO-2306’s potency advantages may not translate in the clinic, and ATTO-1310 may have fewer advantages over Nemluvio beyond dosing frequency. With no marketed products and no revenues, it may need additional capital to fund ongoing R&D and commercialization, while setbacks such as safety signals, regulatory delays, or weaker-than-expected efficacy could materially reduce the probability of success.

ATTO has been analyzed by 5 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 80% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Attovia Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

ATTO Analyst Forecast & Price Prediction

Get the latest ATTO stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in ATTO

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Attovia Therapeutics Inc (ATTO) Forecast

Analysts have given ATTO a Buy based on their latest research and market trends.

According to 5 analysts, ATTO has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $43.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $43.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Attovia Therapeutics Inc (ATTO)


ATTO Analyst Forecast & Price Prediction

Get the latest ATTO stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in ATTO

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover ATTO stock data and trends